santa cruz biotechnology co (Santa Cruz Biotechnology)
Santa Cruz Biotechnology is a verified supplier 
94
Structured Review
Santa Cruz Biotechnology
santa cruz biotechnology co
Santa Cruz Biotechnology Co, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 45 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dr5+sirna/DR5+siRNA/pmc12118949-33-7-7
Average 94 stars, based on 45 article reviews
Santa Cruz Biotechnology Co, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 45 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dr5+sirna/DR5+siRNA/pmc12118949-33-7-7
Average 94 stars, based on 45 article reviews
santa cruz biotechnology co - by Bioz Stars,
2026-09
94/100 stars
Images
Related Articles
Negative Control:Article Title: Cannabidiol Enhances the Therapeutic Effects of TRAIL by Upregulating DR5 in Colorectal Cancer Article Snippet: .. Article Title: Licochalcone B induces DNA damage, cell cycle arrest, apoptosis, and enhances TRAIL sensitivity in hepatocellular carcinoma cells. Article Snippet: Hepatocellular carcinoma (HCC) is a highly fatal disease recognized as a growing global health crisis.. Traditional Chinese herbal medicines have been used to treat patients with cancer for many years in China.. This study investigated the effects of licochalcone B (LCB), a flavonoid compound isolated from the root of Glycyrrhiza uralensis Fisch., on cell proliferation, DNA damage and TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in HCC cells. Article Title: Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5. Article Snippet: Accepted Manuscript Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5 Hong-rong Fei , Chuang Yuan , Gui-ling Wang , Ying Zhao , Zhao-jun Li , Xin Du , Feng-Ze Wang PII: S0944-7113(19)30119-9 DOI: https://doi.org/10.1016/j.phymed.2019.152950 Article Number: 152950 Reference: PHYMED 152950 To appear in: Phytomedicine Received date: 26 December 2018 Revised date: 4 May 2019 Accepted date: 5 May 2019 Please cite this article as: Hong-rong Fei , Chuang Yuan , Gui-ling Wang , Ying Zhao , Zhao-jun Li , Xin Du , Feng-Ze Wang , Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5, Phytomedicine (2019), doi: https://doi.org/10.1016/j.phymed.2019.152950 This is a PDF file of an unedited manuscript that has been accepted for publication.. As a service to our customers we are providing this early version of the manuscript.. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Article Title: Ferroptosis-inducing agents enhance TRAIL-induced apoptosis through upregulation of death receptor 5 Article Snippet: .. Small Interfering RNA:Article Title: Licochalcone B induces DNA damage, cell cycle arrest, apoptosis, and enhances TRAIL sensitivity in hepatocellular carcinoma cells. Article Snippet: Hepatocellular carcinoma (HCC) is a highly fatal disease recognized as a growing global health crisis.. Traditional Chinese herbal medicines have been used to treat patients with cancer for many years in China.. This study investigated the effects of licochalcone B (LCB), a flavonoid compound isolated from the root of Glycyrrhiza uralensis Fisch., on cell proliferation, DNA damage and TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in HCC cells. Article Title: Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5. Article Snippet: Accepted Manuscript Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5 Hong-rong Fei , Chuang Yuan , Gui-ling Wang , Ying Zhao , Zhao-jun Li , Xin Du , Feng-Ze Wang PII: S0944-7113(19)30119-9 DOI: https://doi.org/10.1016/j.phymed.2019.152950 Article Number: 152950 Reference: PHYMED 152950 To appear in: Phytomedicine Received date: 26 December 2018 Revised date: 4 May 2019 Accepted date: 5 May 2019 Please cite this article as: Hong-rong Fei , Chuang Yuan , Gui-ling Wang , Ying Zhao , Zhao-jun Li , Xin Du , Feng-Ze Wang , Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5, Phytomedicine (2019), doi: https://doi.org/10.1016/j.phymed.2019.152950 This is a PDF file of an unedited manuscript that has been accepted for publication.. As a service to our customers we are providing this early version of the manuscript.. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Staining:Article Title: Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5. Article Snippet: Accepted Manuscript Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5 Hong-rong Fei , Chuang Yuan , Gui-ling Wang , Ying Zhao , Zhao-jun Li , Xin Du , Feng-Ze Wang PII: S0944-7113(19)30119-9 DOI: https://doi.org/10.1016/j.phymed.2019.152950 Article Number: 152950 Reference: PHYMED 152950 To appear in: Phytomedicine Received date: 26 December 2018 Revised date: 4 May 2019 Accepted date: 5 May 2019 Please cite this article as: Hong-rong Fei , Chuang Yuan , Gui-ling Wang , Ying Zhao , Zhao-jun Li , Xin Du , Feng-Ze Wang , Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5, Phytomedicine (2019), doi: https://doi.org/10.1016/j.phymed.2019.152950 This is a PDF file of an unedited manuscript that has been accepted for publication.. As a service to our customers we are providing this early version of the manuscript.. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Fluorescence:Article Title: Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5. Article Snippet: Accepted Manuscript Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5 Hong-rong Fei , Chuang Yuan , Gui-ling Wang , Ying Zhao , Zhao-jun Li , Xin Du , Feng-Ze Wang PII: S0944-7113(19)30119-9 DOI: https://doi.org/10.1016/j.phymed.2019.152950 Article Number: 152950 Reference: PHYMED 152950 To appear in: Phytomedicine Received date: 26 December 2018 Revised date: 4 May 2019 Accepted date: 5 May 2019 Please cite this article as: Hong-rong Fei , Chuang Yuan , Gui-ling Wang , Ying Zhao , Zhao-jun Li , Xin Du , Feng-Ze Wang , Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5, Phytomedicine (2019), doi: https://doi.org/10.1016/j.phymed.2019.152950 This is a PDF file of an unedited manuscript that has been accepted for publication.. As a service to our customers we are providing this early version of the manuscript.. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Microscopy:Article Title: Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5. Article Snippet: Accepted Manuscript Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5 Hong-rong Fei , Chuang Yuan , Gui-ling Wang , Ying Zhao , Zhao-jun Li , Xin Du , Feng-Ze Wang PII: S0944-7113(19)30119-9 DOI: https://doi.org/10.1016/j.phymed.2019.152950 Article Number: 152950 Reference: PHYMED 152950 To appear in: Phytomedicine Received date: 26 December 2018 Revised date: 4 May 2019 Accepted date: 5 May 2019 Please cite this article as: Hong-rong Fei , Chuang Yuan , Gui-ling Wang , Ying Zhao , Zhao-jun Li , Xin Du , Feng-Ze Wang , Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5, Phytomedicine (2019), doi: https://doi.org/10.1016/j.phymed.2019.152950 This is a PDF file of an unedited manuscript that has been accepted for publication.. As a service to our customers we are providing this early version of the manuscript.. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Transfection:Article Title: Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5. Article Snippet: Accepted Manuscript Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5 Hong-rong Fei , Chuang Yuan , Gui-ling Wang , Ying Zhao , Zhao-jun Li , Xin Du , Feng-Ze Wang PII: S0944-7113(19)30119-9 DOI: https://doi.org/10.1016/j.phymed.2019.152950 Article Number: 152950 Reference: PHYMED 152950 To appear in: Phytomedicine Received date: 26 December 2018 Revised date: 4 May 2019 Accepted date: 5 May 2019 Please cite this article as: Hong-rong Fei , Chuang Yuan , Gui-ling Wang , Ying Zhao , Zhao-jun Li , Xin Du , Feng-Ze Wang , Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5, Phytomedicine (2019), doi: https://doi.org/10.1016/j.phymed.2019.152950 This is a PDF file of an unedited manuscript that has been accepted for publication.. As a service to our customers we are providing this early version of the manuscript.. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Article Title: Ampelopsin Induces DR5-Mediated Apoptotic Cell Death in EBV-Infected Cells through the p38 Pathway. Article Snippet: Ampelopsin (AMP) is a well-known flavonoid that exerts a number of biological and pharmacological effects including anticancer effects against several cancer cell lines.. In this study, we investigated the anticancer activity of AMP against Epstein-Barr virus (EBV)-positive cells and its mechanism of action.. Our results showed that AMP dose-dependently inhibited cell viability and induced apoptotic cell death in EBV-positive cells without cytotoxicity in EBV-negative cells. Article Title: Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma Article Snippet: Cells were incubated with recombinant human TGF-β1 (10 ng/mL; R&D Systems, Minneapolis, MN, USA) and a combination of the following: TLY012 , anti-DR4 Ab (Mapatumumab; Creative Biolabs, Shirley, NY, USA), anti-DR5 Ab (Conatumumab; Creative Biolabs), Smad 2 inhibitor SB203580 (Selleckchem, Houston, TX, USA), Smad3 inhibitor SIS3 (Selleckchem), or MAPK inhibitor PD98059 (Selleckchem). .. For gene silencing studies, cells were transfected with DR4 siRNA (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), shRNA:Article Title: Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma Article Snippet: Cells were incubated with recombinant human TGF-β1 (10 ng/mL; R&D Systems, Minneapolis, MN, USA) and a combination of the following: TLY012 , anti-DR4 Ab (Mapatumumab; Creative Biolabs, Shirley, NY, USA), anti-DR5 Ab (Conatumumab; Creative Biolabs), Smad 2 inhibitor SB203580 (Selleckchem, Houston, TX, USA), Smad3 inhibitor SIS3 (Selleckchem), or MAPK inhibitor PD98059 (Selleckchem). .. For gene silencing studies, cells were transfected with DR4 siRNA (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), |